Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT03590171 : International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

<17Age Under 17

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAcute Lymphoblastic Leukaemia

Trial Overview Read MoreRead more

A Phase II trial evaluating whether adding bortezomib (an anti cancer drug) to chemotherapy (ALL R3) improves outcomes for patients with acute lymphoblastic leukaemia.
 

This trial is treating patients with acute lymphoblastic leukaemia.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group

Cooperative Group

Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG)

Other Non-Commercial Sponsor

Charite University, Berlin, Germany

Summary

This is a randomised, open-label trial with two arms. Participants in Arm A will receive Backbone ALL R3. Participants in Arm B will receive Backbone ALL Re + Bortezomib. Bortezomib will be administered at 1.3mg/m2 as intravenous bolus or subcutaneously on days 1 and 4 of weeks 1 and 3.

Recruiting Hospitals Read MoreRead more

Monash Children's Cancer Centre
Clayton
Ms Narmatha Kuru
CCCclinicaltrials@monashhealth.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next